News & Events
News & Events
February 12, 2018
Tucson-based Critical Path Institute emerging as top drug-research organizationPresident and CEO Dr. Martha Brumfield was recently interviewed by the Arizona Daily Star for a profile on C-Path published February 11. Dr. Brumfield discusses C-Path’s local ties,expanding global reach, and its recent successes, as well as its groundbreaking collaborative research model. The story outlines the work of C-Path’s consortia in the areas of biomarker...
February 5, 2018
Critical Path to TB Drug Regimens (CPTR) 2018 Annual Workshop, postponedCritical Path Institute and Bill & Melinda Gates Foundation have decided to postpone the Critical Path to TB Drug Regimens Workshop (CPTR) 2018 Annual workshop originally scheduled for April 23-25, 2018. This workshop will be rescheduled later in 2018 to better align with deliverables from our programmatic efforts and alleviate some of the logistical challenges...
January 22, 2018
Critical Path Institute Receives Regulatory Support for Liver Injury BiomarkerTucson, AZ — January 22, 2018 — Critical Path Institute (C-Path) announced today that the European Medicines Agency (EMA) has issued a Letter of Support for measurement of glutamate dehydrogenase (GLDH) as a biomarker of hepatocellular liver injury. The letter was awarded to C-Path’s Predictive Safety Testing Consortium (PSTC) and Duchenne Regulatory Science Consortium (D-RSC)...
January 17, 2018
C-Path welcomes Kay Holcombe to its Board of DirectorsJanuary 17, 2018 TUCSON, Ariz., January 17, 2018 — The Critical Path Institute (C-Path) is pleased to welcome Kay Holcombe to its Board of Directors. Recently retired as Senior Vice President for Science Policy at the Biotechnology Innovation Organization (BIO), Ms. Holcombe brings to the Board her extensive experience in health care and regulatory policy, a...
December 18, 2017
C-Path receives COA qualification from FDA for the Symptoms of Major Depressive Disorder Scale (SMDDS)Tucson, AZ – December 18, 2017 Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its first clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA) for the Symptoms of Major Depressive Disorder Scale (SMDDS). This qualification of the SMDDS for exploratory use represents a major milestone for the...